Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK rearrange |
Therapy | Alectinib + Irinotecan |
Indication/Tumor Type | lung small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange | lung small cell carcinoma | predicted - sensitive | Alectinib + Irinotecan | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Alecensa (alectinib) and Camptosar (irinotecan) resulted in a partial response with progression-free survival lasting longer than 6 months in a small cell lung carcinoma patient harboring an ALK rearrangement (PMID: 34729013). | 34729013 |
PubMed Id | Reference Title | Details |
---|---|---|
(34729013) | ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report. | Full reference... |